

## IN THE SPECIFICATION

Please amend the specification as follows:

Please replace the paragraph starting on page 12, line 10, with the following paragraph:

[0034] The term "lysostaphin," as used herein, encompasses any enzyme or antistaphylococcal agent having proteolytic activity, *in vitro* and *in vivo*, against pentaglycine containing bridges in the cell wall peptidoglycan of staphylococci. Lysostaphin within the scope of the invention encompass: wild-type lysostaphin and related proteins or antistaphylococcal agents, lysostaphin mutants, variants, fully synthetic and partially synthetic lysostaphins, and recombinantly expressed lysostaphin proteins. Lysostaphin variants may be generated by post-translational processing of the protein (either by enzymes present in a producer's strain or by means of enzymes or reagents introduced at any stage of the process, or by mutation of the structural gene. Mutations may include site-deletion, insertion, point mutations, domain removal and replacement mutations. Lysostaphin includes, for example, Lysostaphin purified from *S. simulans*, AMBICIN L ~~Ambicin L~~ (recombinant lysostaphin produced in *Bacillus sphaericus* and available from NUTRITION 21 ~~Nutrition 21~~ (formerly AMBI) of Purchase, NY), and mature Lysostaphin purified from a *Lactococcus lactis* expression system or an *E. coli* expression system, and truncated lysostaphin as set forth in co-pending and commonly owned WO 03/082124, U.S. Pat. App. Serial No. 10/499,690 filed January 18, 2005 published as U.S. Pat. App. Pub. No. 20050118159 on June 2, 2005, specifically incorporated by reference herein.